Better Buy: Crispr Therapeutics vs. Editas
In 2019, the art of fixing the troublesome gene mutations known to cause severe, life-threatening illnesses took some big steps forward. That helped investors who began 2019 with shares of Crispr Therapeutics (NASDAQ: CRSP) and Editas Medicine (NASDAQ: EDIT), two gene-editing pioneers, record some market-beating gains.
Which one has the best chance to beat the market again in 2020 and beyond? When it comes to gene-editing stocks, there are a lot of ins and outs to consider. Let's lay the most important ones side by side to see which is the better buy right now.
Image source: Getty Images.
Source Fool.com
